A case report of unresectable BRAF-wildtype ATC with programmed death-ligand 1 (PD-L1) expression >90%, in which treatment with lenvatinib and pembrolizumab for one month allowed tumor resection, achieved disease stability for at least 11 months [71]. The gene discussed is BRAF; the disease is neoplasm.